ScholarLens Back to search
2021•JAAD Case ReportsOpen access

Rapid and sustained remission of synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome with IL-23p19 antagonist (risankizumab)

Akshay Flora, Richard Holland, Annika Smith, John W. Frew

Open full text 18 citations

Abstract

Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is an uncommon autoinflammatory syndrome, with an estimated prevalence of 1 in 10,000 in the Caucasian population.1 SAPHO is defined by the diagnostic criteria proposed by Kahn et al,2 which includes either a chronic multifocal sterile osteomyelitis, sterile osteitis, or arthritis.1,3 The latter 2 require at least 1 accompanying dermatologic feature, which includes palmoplantar pustulosis, pustular psoriasis, or severe acne.

About this research paper

What this paper is about

Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is an uncommon autoinflammatory syndrome, with an estimated prevalence of 1 in 10,000 in the Caucasian population.1 SAPHO is defined by the diagnostic criteria proposed by Kahn et al,2 which includes either a chronic multifocal sterile osteomyelitis, sterile osteitis, or arthritis.1,3 The latter 2 require at least 1 accompanying dermatologic feature, which includes palmoplantar pustulosis, pustular psoriasis, or severe acne.

Why it matters

OpenAlex reports 18 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is an uncommon autoinflammatory syndrome, with an estimated prevalence of 1 in 10,000 in the Caucasian population.1 SAPHO is defined by the diagnostic criteria proposed by Kahn et al,2 which includes either a chronic multifocal sterile osteomyelitis, sterile osteitis, or arthritis.1,3 The latter 2 require at least 1 accompanying dermatologic feature, which includes palmoplantar pustulosis, pustular psoriasis, or severe acne.

Key concepts: SAPHO syndrome, Palmoplantar pustulosis, Pustulosis, Medicine, Hyperostosis, Osteitis, Synovitis, Dermatology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Rapid and sustained remission of synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome with IL-23p19 antagonist (risankizumab) — Research Paper | ScholarLens